OptimizeRx (NASDAQ:OPRX) Given New $16.00 Price Target at Stifel Nicolaus

OptimizeRx (NASDAQ:OPRX) had its price target hoisted by Stifel Nicolaus from $12.50 to $16.00 in a research note issued to investors on Monday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

OPRX has been the subject of a number of other reports. JMP Securities increased their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 13th. Wall Street Zen raised OptimizeRx from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Roth Capital reissued a “buy” rating on shares of OptimizeRx in a report on Tuesday, May 13th. B. Riley reaffirmed a “buy” rating on shares of OptimizeRx in a report on Tuesday, May 13th. Finally, Citigroup reiterated an “outperform” rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and an average target price of $10.81.

OptimizeRx Trading Up 1.0%

OptimizeRx stock opened at $14.76 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $15.25. The firm’s 50-day moving average is $10.11 and its 200-day moving average is $7.33. The company has a market cap of $272.99 million, a P/E ratio of -11.10 and a beta of 1.34.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%. The firm had revenue of $21.93 million during the quarter, compared to the consensus estimate of $18.69 million. On average, equities analysts expect that OptimizeRx will post -0.33 earnings per share for the current year.

Insider Buying and Selling

In other OptimizeRx news, Director James Paul Lang bought 321,408 shares of the stock in a transaction on Friday, March 14th. The shares were bought at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the purchase, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 5.60% of the company’s stock.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds have recently modified their holdings of the stock. SBI Securities Co. Ltd. acquired a new position in OptimizeRx in the 4th quarter worth about $25,000. GAMMA Investing LLC acquired a new stake in shares of OptimizeRx during the 1st quarter valued at about $33,000. SG Americas Securities LLC bought a new stake in shares of OptimizeRx in the 4th quarter valued at approximately $51,000. Wells Fargo & Company MN increased its holdings in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after buying an additional 2,797 shares during the last quarter. Finally, Graham Capital Management L.P. bought a new position in OptimizeRx during the fourth quarter valued at approximately $81,000. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.